The Railway Recruitment Board has released the results for the RPF Sub-Inspector recruitment exam 2025. Out of over 1.5 million candidates, 4,527 have qualified for the next stage involving PET ...

The UC space is highly diversified with a number of molecules approved. In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist developed by Eli Lilly. It is indicated ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...

Layers have long been a cornerstone of full, bouncy tresses, while curtain and wispy bangs offer an introduction to fringe without a bold, blunt cut. And when these two characteristics come together?

Compared to Dave, the judge is a purring kitten. The Rule Of Jenny Pen is a phenomenal exercise in character development, but that’s just one of the incredible tools that is utilized in crafting ...

The 69-year-old momager showed off a chic bob on Instagram on March 24, opting for longer locks than her usual signature pixie cut. She slicked her dark hair back and down, where it sat neatly ...

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to ...

Other IL-23 inhibitors approved for Crohn's disease include risankizumab (Skyrizi) and mirikizumab (Omvoh). Common adverse events (≥3%) with guselkumab in the Crohn's disease trials included ...

The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla, approvals of new indications for existing Lilly medicines ...

Data captured from pediatric patients revealed a relationship between high burden of common infection episodes in early life and increased risk for moderate to severe infections in later childhood ...